CompletedNot Applicable

Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

Spain230 participantsStarted 2024-02-21

Plain-language summary

Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Complejo Hospitalario Universitario de Albacete" (CHUA). Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Admitted to the hospital CHUA
✓. Meet the SARS-CoV-2 diagnostic criteria with positive PCR
✓. They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol).

Exclusion criteria

✕. Patients who do not receive the full first dose of Calcifediol within the first 72 hours.
✕. Patients for whom electronic medical record data cannot be collected.
✕. Patients with other serious intercurrent diseases (eg advanced oncological pathology).

What they're measuring

Measure mortality by differentiating groups: calcifediol yes/no.

Timeframe: 02/21/2024 to 04/25/2024

Measure the need for ICU admission by differentiating the groups calcifediol yes/no.

Timeframe: 02/21/2024 to 04/25/2024

Trial details

NCT IDNCT06279910

SponsorComplejo Hospitalario Universitario de Albacete

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-21

View on ClinicalTrials.gov More SARS-CoV 2 Pneumonia trials